CD19 and systemic sclerosis: In the most recent reports, as of June 2023, the Erlangen (Germany) team has administered CD19-targeted CAR-T therapy to eight patients with treatment-resistant SLE, with the longest follow-up period extending to 24 months [30], as well as three idiopathic inflammatory myopathy patients and four SSc patients [31].